Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Speaking of interesting:
https://www.emdgroup.com/en/news/allergopharma-19-02-2020.html
(Apologies if this has already been posted)
Senti.....
Your efforts are very much appreciated - Thank You!
Reference: UCLA Brain Tumor Center - 2.12.2020
Noted as one of the UCLA speakers at this event is Dr. Phioanh Nghiemphu. Dr. Nghiemphu is listed on the Global Coalition for Adaptive Research site as investigator for upcoming UCLA GBM AGILE trial:
“WHAT IS GBM AGILE?
GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) is a flexible and adaptable trial approach that evaluates several treatment arms simultaneously and/or over time, giving it the potential to fundamentally change the clinical research process for glioblastoma (GBM) by identifying or disproving therapies more quickly. This will help to usher in a new generation of effective treatments for GBM, the most common and the deadliest type of brain cancer.”
“Coming Soon!”
University of California, Los Angeles (Los Angeles, CA)
Principal Investigator: Phioanh Nghiemphu, MD
https://www.gcaresearch.org/gbm-agile/trial-sites/
Noted: On the GBM AGILE's Knowledge Network are the names of:
TIMOTHY F. CLOUGHESY, M.D
LINDA LIAU, M.D., PH.D., M.B.A.
IWD....
Many of us will start our day with your most encouraging and appropriate post on this World Cancer Day - February 4th.
Indeed, shame, shame shame…..
Most innovative cancer drugs facing delays in reaching patients
“It is taking longer for new drugs to reach patients and, alarmingly, the delays are longest for the most exciting, innovative treatments, with the greatest potential to transform the lives of patients.”
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London
https://www.firstwordpharma.com/node/1696886?tsid=28®ion_id=4
8K-INmune SEC filing - LP shares
https://www.inmunebio.com/index.php/en/investors/filings
“Item 1.01 Entry Into a Material Definitive Agreement
On January 27, 2020, INmune Bio, Inc. (the “Company”) entered into an agreement (the “Repurchase Agreement”) to purchase 220,000 shares of its common stock, par value $0.001 per share (the “Shares”) from Linda F. Powers. The purchase price is $4.60 per share, resulting in a total purchase price of $1,012,000 (the “Repurchase Transaction”) which the company believes is an attractive price and will be accretive. Prior to consummating the Repurchase Transaction, Ms. Powers held approximately 10.4% of the Company’s outstanding common stock. Following the consummation of the Repurchase Transaction, Ms. Powers now holds approximately 8.6% of the Company’s outstanding common stock. The Repurchase Agreement and the transactions contemplated therein, were approved by the Company’s board of directors and audit committee.
The foregoing is merely a brief description of the material terms of the Repurchase Agreement, which is attached hereto as Exhibit 10.1 and incorporated herein by reference. The foregoing does not purport to be a complete description of the rights and obligations of the parties thereunder and such description is qualified in its entirety by reference to such exhibit.”
Upon reading this INmune article, I sense something and feel it would be prudent to keep my thoughts to myself at this time…..so, I will just post the link. Many of you are good at reading between the lines, n’est pas?
https://www.cfodive.com/news/INmune-Bio-simplified-biopharma-cap-structure/570538/
Has this filing been posted?
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1072379/000110465920004348/tm203525-1_424b5.htm
It’s getting worser and worser….send me some chocolate.
Of interest:
NICE issues draft guidance rejecting Merck & Co.'s Keytruda in first-line head and neck cancer
https://www.firstwordpharma.com/node/1693841?tsid=28®ion_id=6
Slightly amused this morning in reading this recap of the upcoming JP Morgan conference:
JP Morgan Preview: Small, Medium and Large, with a Lot of M&A Speculation
(…..ending paragraph)
“What would be surprising is if there WASN’T a surprise announcement at the conference. Stay tuned!”
https://www.biospace.com/article/jp-morgan-preview-small-medium-and-large-with-a-lot-of-m-and-a-speculation/
Warm wishes and prayers on the way to you.
From the Medivate Partners website - Portfolio listing
Medivate Partners was one of the principals in the management buyout in February 2018:
Cognate[color=red][/color]
homepage | https://www.cognatebioservices.com/
Cognate BioServices, Inc. is one of four well established contract manufacturing organizations (CMO) in the United States, with expertise in the clinical and commercial development, and manufacturing of cell therapies. Cognate is the only CMO to date capable of commercial scale manufacturing of cell therapies, with global No1. Capacity. Cognate has unparalleled experience in providing personalized immuno-oncology products in the largest PhIII cell- therapy clinical trial. With the
serif; font-size: 9pt;'>Cognate is the only CMO to date capable of commercial scale manufacturing of cell therapies, with global No1. Capacity. Cognate has unparalleled experience in providing personalized immuno-oncology products in the largest PhIII cell- therapy clinical trial.
With the recent FDA approval of the first cell-based/immuno-oncology therapeutics, (CAR-T), rapid expansion of the cell therapy market is expected. Such favorable market dynamics will provide the cornerstone for Cognate’s further success
http://www.medivatepartners.com/en/html/current.html
It is apparent that you live and practice in the divine light.
“Wherever the art of Medicine is loved, there is also a love of Humanity.” — Hippocrates
Thank you for the time clarification Flipper
Marzan, I idon't have a time; here is the lineup:
Linda Liau @ Baptist Nov 6, 2019 - Continuing Medical Education
“Miami Brain Symposium Evaluation” (score sheet for attendees)
https://cmeonline.baptisthealth.net/content/miami-brain-symposium-evaluation-december-6-2019
List of Abstracts re: Novocure's presentations:
https://www.biospace.com/article/releases/novocure-announces-43-presentations-on-tumor-treating-fields-at-24th-annual-meeting-of-the-society-for-neuro-oncology/
Interesting side note to the Sue Keil (NWBO) thread:
INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia Allen …..(Nov 19, 2019)
“Marcia is recognized as a leader in the financial community and brings a unique, broad ranging international experience to the Board that further strengthens our team,” said RJ Tesi, MD, INmune Bio’s Chief Executive Officer and Chief Medical Officer. “Her public company experience and financial expertise will be invaluable as we continue to grow the company.”
…..”She has more than 25 years with mergers and acquisitions, corporate finance and CFO and CEO experience.”
“INmune Bio has a remarkable opportunity to address an array of ineffectively treated diseases with its platform solutions, and I look forward to helping guide the company in the execution of its strategy through the next phases of its development,” said Allen.
https://www.globenewswire.com/news-release/2019/11/19/1949496/0/en/INmune-Bio-Inc-Strengthens-Board-of-Directors-with-Appointment-of-Veteran-Finance-Executive-Marcia-Allen.html
Ditto here, Beartrap
Having trouble most of the day....ahhhh
Congratulations! Marzan. You deserve the AMRN reward. Thank you, too, for your continual supportive efforts and substantive posts on the NWBO board.
Thanks Sojourner
I recall that one of the Apple agents did this (blocking) for the “PartyClub” website but not the IHub site.
I have been on the phone with Apple Help all morning ( 3 hours - 3 different agents ) - They seem to be stumped. Everytime it clears up and I think I am on a go-ahead, it returns.
“ML has clear links with LP, Advent, NWBO, and Cognate (through J Kelly Ganjei), and they're only the ones we know about.”
INMune Bio
Professor Mark Lowdell, PhD
CSO/CMO
Prof. Lowdell has been a Chief Scientific Officer and Chief Manufacturing Officer since the formation of the Company in September 2015. Prof. Lowdell is Professor of Cell and Tissue Therapy at University College London, where he has led a translational immunotherapy group since 1994. Since February 2009, Prof. Lowdell has also been Director of Cellular Therapy at the Royal Free London NHS Foundation Trust. He received his PhD in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.
Cognate BioServices announces acquisition of Cobra Biologics
https://www.cognatebioservices.com/cognate-bioservices-announces-acquisition-of-cobra-biologics/
An interesting interview with Merck’s Perlmutter. I was amused at the reference to “orange juice” in this exhange:
“Xconomy: Several oncologists believe there isn’t enough basic research and too much spaghetti-against-the-wall when it comes to clinical trials for combinations. What is your response?
RP: The philosophical underpinnings of our approach have integrity. It’s not like we do everything. To those who are concerned that we’re just saying, “Oh, what the hell, let’s try anything, orange juice, mineral oil, whatever”—we are thinking this through very carefully. Among the literally hundreds of things we could do, we select just a few. Although we have more than 450 combination studies ongoing, it’s the product of a very thoughtful, precise selection.”
Merck’s Perlmutter interview regarding Keytruda (Jan 2019)
https://xconomy.com/national/2019/01/16/merck-and-the-future-of-immuno-oncology-a-chat-with-roger-perlmutter/